ADDF grants Signum Biosciences $270.

Dr. Gregory Share, Signum’s CEO, said: We are honored to become selected for just one of ADDF’s highly competitive, peer-examined grants. The course of STMs we are analyzing pre-clinically has yielded positive pilot outcomes in a transgenic Alzheimer’s mouse model. This grant will accelerate the progress of both our pharmaceutical qualified prospects and a related small molecule that is clearly a minimal constituent of coffee. Numerous studies show that consumption of coffee is correlated with minimal incidence of Alzheimer’s, so this coffee component may provide a neuroprotective medical meals to serve as a near-term stopgap against the condition. SOURCE Alzheimer’s Medication Discovery Foundation..Related StoriesNew findings reveal association between colorectal cancers and melanoma drug treatmentMeat-rich diet may increase kidney cancer riskSausages With Antioxidants From Berries To Prevent Tumor We are delighted to provide updated medical data for the DIGNITY study at this prominent meeting as the radiation oncology community is a key partner in treating the RCW breasts cancer population, said Michael H. Tardugno, Celsion’s President and CEO.